This therapy must be given within the first 10 days of COVID-19 symptoms. Contact your AHN provider as soon as you start to feel symptoms or think you’ve been exposed to Coronavirus to coordinate COVID-19 testing. If you have COVID-19 and if you’re eligible, your provider will provide next steps and direct you to the appropriate AHN facility.
Monoclonal antibody infusion therapy uses antibodies administered through an IV to help treat mild to moderate COVID-19 cases in non-hospitalized, high-risk patients. This therapy received emergency use authorization (EUA) from the Food and Drug Administration for use with Coronavirus patients.
We have recently switched to using only Sotrovimab – the monoclonal antibody with effectiveness against the omicron variant of the COVID-19 virus. The omicron variant is currently the dominant variant in the US, and previous formulations of monoclonal antibodies are not effective against it.
Because Sotrovimab is in short supply, AHN prioritizes our highest-risk patients, 18 and older, for this therapy. As supplies increase, we will broaden eligibility.
High-risk patients:
Additional criteria:
Call your AHN provider to discuss your appropriate next steps. If you do not have a primary care provider, you can schedule a virtual urgent care visit with AHN.
Yes. Monoclonal antibodies have been used in clinical settings for years. Mild side effects have been reported, but are generally uncommon. You’ll also be closely monitored after your infusion for any reactions.
This therapy has been closely studied and can reduce the likelihood of hospitalization or death for COVID-19 patients who have mild to moderate symptoms.
Vaccination and boosters do not affect your eligibility to receive monoclonal antibody infusion therapy. AHN encourages all eligible patients to receive their vaccine or booster.
However, once a patient does receive this therapy, any COVID-19 vaccine dose or booster must be delayed for 90 days.
